Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

arcellx inc - ACLX

ACLX

Close Chg Chg %
66.75 3.11 4.66%

Pre-Market

69.86

+3.11 (4.66%)

Volume: 854.41K

Last Updated:

Jan 14, 2026, 4:00 PM EDT

Trade Now

Company Overview: arcellx inc - ACLX

ACLX Key Data

Open

$66.53

 Day Range

65.10 - 69.89

52 Week Range

47.86 - 94.07

 Market Cap

$3.75B

Shares Outstanding

57.82M

 Public Float

43.57M

Beta

0.36

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.92

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

884.99K

  

ACLX Performance

1 Week
 
 5.42%
 
1 Month
 
 -2.78%
 
3 Months
 
 -19.69%
 
1 Year
 
 5.08%
 
5 Years
 
 N/A
 

ACLX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About arcellx inc - ACLX

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

ACLX At a Glance

Arcellx, Inc.
800 Bridge Parkway
Redwood City, California 94065
Phone 1-240-327-0630 Revenue 107.94M
Industry Biotechnology Net Income -107,348,000.00
Sector Health Technology Employees 163
Fiscal Year-end 12 / 2025
View SEC Filings

ACLX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 38.059
Price to Book Ratio 9.155
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -27.001
Enterprise Value to Sales 33.117
Total Debt to Enterprise Value 0.015

ACLX Efficiency

Revenue/Employee 662,184.049
Income Per Employee -658,576.687
Receivables Turnover N/A
Total Asset Turnover 0.14

ACLX Liquidity

Current Ratio 4.779
Quick Ratio 4.779
Cash Ratio 4.685

ACLX Profitability

Gross Margin 95.193
Operating Margin -127.456
Pretax Margin -97.538
Net Margin -99.455
Return on Assets -13.973
Return on Equity -22.836
Return on Total Capital -21.095
Return on Invested Capital -20.692

ACLX Capital Structure

Total Debt to Total Equity 11.891
Total Debt to Total Capital 10.627
Total Debt to Total Assets 7.603
Long-Term Debt to Equity 10.234
Long-Term Debt to Total Capital 9.146
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Arcellx Inc - ACLX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - 110.32M 107.94M
-
Sales Growth
- - - -2.16%
-
Cost of Goods Sold (COGS) incl D&A
1.04M 2.22M 2.04M 5.19M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.04M 2.22M 2.04M 5.19M
Depreciation
1.04M 2.22M 2.04M 5.19M
Amortization of Intangibles
- - - -
-
COGS Growth
+65.50% +113.64% -8.27% +154.31%
Gross Income
(1.04M) (2.22M) 108.28M 102.75M
Gross Income Growth
-65.50% -113.64% +4,968.66% -5.11%
Gross Profit Margin
- - +98.15% +95.19%
-
2021 2022 2023 2024 5-year trend
SG&A Expense
63.98M 189.03M 198.16M 240.32M
Research & Development
46.88M 149.56M 133.85M 157.09M
Other SG&A
17.09M 39.48M 64.31M 83.23M
SGA Growth
+103.31% +195.47% +4.83% +21.28%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(65.02M) (191.26M) (89.88M) (137.57M)
Non Operating Income/Expense
49.00K 4.30M 23.70M 33.32M
Non-Operating Interest Income
- - - 300.00K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 1.72M 3.84M 1.03M
Interest Expense Growth
- - +123.37% -73.19%
-
Gross Interest Expense
- 1.72M 3.84M 1.03M
Interest Capitalized
- - - -
-
Pretax Income
(64.97M) (188.68M) (70.03M) (105.28M)
Pretax Income Growth
-102.43% -190.41% +62.89% -50.34%
Pretax Margin
- - -63.48% -97.54%
-
Income Tax
- - 663.00K 2.07M
-
Income Tax - Current - Domestic
- 19.09M 663.00K 2.07M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - (19.09M)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(64.97M) (188.68M) (70.69M) (107.35M)
Minority Interest Expense
- - - -
-
Net Income
(64.97M) (188.68M) (70.69M) (107.35M)
Net Income Growth
-102.43% -190.41% +62.53% -51.86%
Net Margin Growth
- - -64.08% -99.46%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(64.97M) (188.68M) (70.69M) (107.35M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(64.97M) (188.68M) (70.69M) (107.35M)
EPS (Basic)
-1.818 -4.2779 -1.4708 -2.004
EPS (Basic) Growth
-90.01% -135.31% +65.62% -36.25%
Basic Shares Outstanding
35.74M 44.11M 48.06M 53.57M
EPS (Diluted)
-1.818 -4.2779 -1.4708 -2.004
EPS (Diluted) Growth
-90.01% -135.31% +65.62% -36.25%
Diluted Shares Outstanding
35.74M 44.11M 48.06M 53.57M
EBITDA
(63.98M) (189.03M) (87.84M) (132.38M)
EBITDA Growth
-103.31% -195.47% +53.53% -50.71%
EBITDA Margin
- - -79.62% -122.65%
-

Snapshot

Average Recommendation BUY Average Target Price 112.313
Number of Ratings 19 Current Quarters Estimate -1.122
FY Report Date 03 / 2026 Current Year's Estimate -3.301
Last Quarter’s Earnings -1.054 Median PE on CY Estimate N/A
Year Ago Earnings -4.055 Next Fiscal Year Estimate -1.87
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 19 14
Mean Estimate -1.12 -1.19 -3.30 -1.87
High Estimates -0.97 -0.98 -0.24 1.57
Low Estimate -1.27 -1.38 -5.17 -4.62
Coefficient of Variance -7.94 -10.86 -45.92 -89.98

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 15 16
OVERWEIGHT 1 1 2
HOLD 2 2 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Arcellx Inc - ACLX

Date Name Shares Transaction Value
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 64,832 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 43,199 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 30,135 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 13,615 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 13,021 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 61,590 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 20,496 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 88,542 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Christopher R. Heery CHIEF MEDICAL OFFICER 67,708 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 44,302 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Michelle Gilson CHIEF FINANCIAL OFFICER 28,962 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 167,973 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 55,459 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 208,333 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 782,467 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 726,476 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 8, 2026 Rami Elghandour SEE REMARKS; Director 673,378 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Arcellx Inc in the News